Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.


French German Italian Portuguese Russian

Drug Treatment Study for Children with Hemophilia A

Clinical Trial Title: 
Safety and efficacy of turoctocog alfa pegol (N8-GP) in previously untreated patients with hemophilia A.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Mindy Simpson, MD
Clinical Trial Protocol Description: 

Phase 3a open-label trial investigating the safety and efficacy of N8-GP (a recombinant, extended half-life factor VIII concentrate) for prophylaxis and treatment of bleeding episodes.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have hemophilia A.
  • Are a male.
  • Are 6 years of age or younger.
  • Have never received any factor medications or blood products.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-3034
Contact Name: 
Mindy Simpson, MD